AI Article Synopsis
- SARS-CoV-2, the virus behind COVID-19, is responsible for a global pandemic, severely straining healthcare systems worldwide.
- COVID-19 patients face an increased risk of thromboembolic complications due to factors like inflammation, endotheliitis, hyperviscosity, and hypercoagulability.
- A comprehensive review of existing literature was conducted using databases like PubMed, EMBASE, and CINAHL to explore the epidemiology, clinical characteristics, mechanisms, and treatment options related to COVID-19-associated coagulopathy.
Article Abstract
The SARS-CoV-2 is a new coronavirus responsible for the COVID-19 disease and has caused the pandemic worldwide. A large number of cases have overwhelmed the healthcare system worldwide. The COVID-19 infection has been associated with a heightened risk of thromboembolic complications. Various mechanisms are leading to the high thrombotic risk in COVID-19 patients such as inflammation, endotheliitis, hyperviscosity, and hypercoagulability. We searched PubMed, EMBASE, and CINAHL from January 2020 to December 2020. We used the following search terms: COVID-19, coagulopathy, and thrombosis. We reviewed the epidemiology, clinical features, mechanisms, and treatment of COVID-19-associated coagulopathy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444678 | PMC |
| http://dx.doi.org/10.1111/crj.13438 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!